Company intelligence / Profile preview
Faeth Therapeutics
Austin, Texas, United Statesfaeththerapeutics.com ↗
- Ownership
- Public · FTH
- Development stage
- Phase 1
01
Overview
Faeth's lead program, PIKTOR (combination of FTH-001/serabelisib and FTH-003/sapanisertib with paclitaxel), has shown outstanding clinical results and is now in a Phase 2 trial for patients with endometrial cancer[7].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesPrecision nutrition
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
The GOG Foundation, Inc. (GOG-F)
04
Financials
- Market cap
- $513.5M
- Total revenue
- $0
- Enterprise value
- $338.9M
Beyond the preview
Go deeper on Faeth Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Faeth Therapeutics.